Patients on benralizumab, dupilumab, or mepolizumab have lower post-vaccination SARS-CoV-2 immunityArticle Published on 2024-06-012024-09-05 Journal: The Journal of Allergy and Clinical Immunology [Category] update2024, [키워드] Antibody neutralization Asthma biologics benralizumab COVID-19 Dupilumab memory B cells memory T cells mepolizumab mRNA vaccines SARS-CoV-2 [DOI] 10.1016/j.jaci.2024.03.029 PMC 바로가기 [Article Type] Article
Unanswered questions on the use of biologics in pediatric asthmaReview Published on 2023-11-032024-09-04 Journal: The World Allergy Organization Journal [Category] 대상포진, [키워드] benralizumab biologics Dupilumab mepolizumab omalizumab Severe childhood asthma Tezepelumab [DOI] 10.1016/j.waojou.2023.100837 PMC 바로가기 [Article Type] Review
Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of LifeOutcome Measures Published on 2023-06-272024-09-04 Journal: Dermatology (Basel, Switzerland) [Category] 대상포진, [키워드] Chronic prurigo Dupilumab Quality of life [DOI] 10.1159/000531708 PMC 바로가기 [Article Type] Outcome Measures
Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysisReview Article Published on 2023-06-022024-09-04 Journal: Heliyon [Category] 대상포진, [키워드] abrocitinib Dupilumab Meta-analysis Moderate-to-severe atopic dermatitis Randomized controlled trials Upadacitinib [DOI] 10.1016/j.heliyon.2023.e16704 PMC 바로가기 [Article Type] Review Article
Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerationsArticle Published on 2023-04-282024-09-04 Journal: The journal of allergy and clinical immunology. In [Category] 대상포진, [키워드] abrocitinib atopic dermatitis Baricitinib biologics cytokine signaling Dupilumab eczema interleukin-13 Interleukin-4 Janus kinase inhibitor lebrikizumab nemolizumab tralokinumab Upadacitinib [DOI] 10.1016/j.jaip.2023.03.011 PMC 바로가기 [Article Type] Article
Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Managementarticle Published on 2023-04-152024-09-02 Journal: Cornea [Category] 대상포진, [키워드] belantamab mafodotin Dupilumab ocular surface disease tralokinumab [DOI] 10.1097/ICO.0000000000003162 PMC 바로가기 [Article Type] article
COMPARATIVE EFFECTIVENESS OF OMALIZUMAB, MEPOLIZUMAB, AND DUPILUMAB IN ASTHMA: A TARGET TRIAL EMULATIONArticle Published on 2023-02-072024-09-05 Journal: The Journal of Allergy and Clinical Immunology [Category] update2024, [키워드] allergic Asthma comparative effectiveness Dupilumab Eosinophilic mepolizumab monoclonal antibodies omalizumab Target trial emulation [DOI] 10.1016/j.jaci.2023.01.020 PMC 바로가기 [Article Type] Article
The impact of dupilumab treatment on SARS-CoV-2 T cell responses in atopic dermatitis patientsArticle Published on 2023-02-012023-07-10 Journal: Allergy [Category] COVID19(2023년), [키워드] atopic dermatitis COVID-19 Dupilumab SARS-CoV-2 T cell [DOI] 10.1111/all.15540 PMC 바로가기
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with DupilumabBrief Report Published on 2022-11-012024-09-04 Journal: Advances in therapy [Category] 대상포진, [키워드] Adults atopic dermatitis clinical trials Dupilumab infections long-term Safety [DOI] 10.1007/s12325-022-02322-y PMC 바로가기 [Article Type] Brief Report
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experienceArticle Published on 2022-08-012022-11-15 Journal: Journal of the European Academy of Dermatology and [Category] COVID19(2023년), SARS, 진단, [키워드] adverse event adverse events age approved Asymptomatic atopic dermatitis baseline clinical phenotype clinical phenotypes clinical trials collected conducted COVID-19 pandemic disease dosage drug Dupilumab effective Effectiveness enrolled evaluated examined Flexural eczema Italian multicentre outcome Patient phenotype Phenotypes reported safety profile SARS-COV-2 infection Side-effects treated Treatment treatment period [DOI] 10.1111/jdv.18141 PMC 바로가기